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etters to the Editor - Case Report
cute pancreatitis as initial manifestation in an
dult patient with focal proliferative necrotizing
urpura nephritisancreatitis aguda como manifestación inicial en un paciente adulto
on purpura y glomerulonefritis necrosante proliferativa focalear Editor,
enoch–Schönlein purpura (HSP) is a generalized vasculitis,
hich could cause a large variety of symptoms in different
rgans. Acute pancreatitis is an inﬂammatory disorder and
ay be life-threatening if it is severe. HSP could cause the
cute pancreatitis rarely. It tends to develop in the ﬁrst week
f the illness after characteristic purpura, or develop later.1
xceptionally, acute pancreatitis developed during the course
f HSPN as an initial presenting feature before the typical rash.
erewe report an adult patientwithHSPNpresenting after the
cute pancreatitis.
A 19-year-old man was admitted to our hospital with the
hief complaint of “abdominal pain and abnormal urine test
or 1 month, erythematosus purpura over legs for 5 days”.
e received the treatment for pancreatitis in the local hos-
ital. However, the pancreatitis did not get remission. On
dmission of our hospital, the patient had a normal blood
ressure and respiratory rate. There was a diffuse purpuric
ash located over the legs. Abdominal examination showed
enderness in all quadrants with rebound tenderness. There
as no hepatosplenomegaly, and bowel sounds were nor-
al. Blood testing showed hemoglobin (101 g/l), white cell
ount (19.6×109 g/l), neutrophil (9.7×109 g/l). Erythrocyte sed-
mentation rate and C-reactive protein were signiﬁcantly
igh at 29mm/h and 100.3mg/l, respectively. Serum testing
howed glucose (3.3mmol/l), urea (6.31mmol/l), creatinine
52umol/l), albumin (28.5 g/l), total cholesterol (4.1mmol/l),
nd triglyceride (1.6mmol/l). Serum amylase (332U/l) and
ipase (85.2U/l) were increased. Urinary sediment examina-
ion showed microscopic hematuria. The proteinuria of 24h
s 2.48 g/2 L. Rheumatoid factor and complements (C3, C4)
ere within the normal range, and antinuclear antibodies,anti-DNA, antiphospholipids, antineutrophil cytoplasmic
antibodies, and hepatitis viral markers were negative. Abdom-
inal ultrasound showed a peritoneal effusion. Abdominal
computed tomography (CT) scan noted an edematous pan-
creas (Fig. 1).
The result of renal biopsy was focal proliferative necro-
tizing purpura nephritis. Focal granular staining for IgA and
C3 in the mesangium was shown using immunoﬂuorescence
staining. By light microscopy, glomeruli showed a mild hyper-
cellularity in mesangial cells and matrix, focal endocapillary
hypercellularity, eight crescents of 10 glomerulis, 1 necrosis
of capillary loop. There is interstitial edema and inﬂamma-
tion composed mainly of mononuclear leukocytes and tubular
epithelial injury (Fig. 2). The result of the light microscopy was
conﬁrmed by the electron microscopy.
The patient was diagnosed as purpura nephritis com-
plicated by acute pancreatitis. He was started on therapy
with methylprednisolone 40mg/d intravenously for 5 days
before the renal biopsy result. Afterwards, 0.5 g bolus of
methylprednisolone was given intravenously for 3 days and
after that prednisone orally (30mg/day) and MMF orally
(1.5mg/day). Abdominal pain disappeared at the third day of
the treatment and the pancreas was normal after two weeks’
treatment. After 1-year follow-up, the patient recovered well
with prednisone (10mg/day) and MMF (0.25mg/d), and renal
function was normal, proteinuria was less than 150mg/day,
and abdominal CT scan was normal.
The association between pancretitis and Henoch–
Schönlein Purpura Nephritis is rare. In our case, purpura
nephritis complicated by acute pancreatitis was showed in
this 19-year-old man. HSP is a rare cause of acute pancre-
atitis that can occur before or after the characteristic rash.
In our case, the symptoms occurred before the rash. The
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Fig. 1 – Edematous pancreas in abdominal CT scan.pancreatitis tends to develop on the ﬁrst day of the illness
but may develop as late as day 75.2 Acute pancreatitis is
presumed to be caused by vasculitic involvement of the
pancreas.
The clinical feature of HSP nephritis is quite variable.
The pathology of this patient showed a mild hypercel-
lularity in mesangial cells and matrix, focal endocap-
illary hypercellularity, eight crescents of ten glomerulis,
1 necrosis of capillary loop. In the literature, only two
Fig. 2 – Crescents observed by light microscopy in Masson












cases got renal biopsy of purpura nephritis with pan-
cretitis. One case showed moderate-to-severe increase
of mesangial matrix with crescent formation3 and one
case showed endocapillary proliferative glomerulonephritis.2
There is no special feature in the pathology of those
patients.
Steroids have been used to treat HSP patients with
pancretitis.4–7 For most HSP related pancretitis without
nephritis, parenteral nutrition and Nasogastric suction was
used to treat the pancretitis,8,9 and the outcome of pancreti-
tis improved. In our case, the patient’s pancretitis did not
improve with the supportive treatment; however, the symp-
toms of pancretitis disappeared with the steroids usage. In
the literature, two patients were diagnosed as HSP related
pancretitis with nephritis. In the study by Frirui et al., kidney
biopsy showed endocapillary proliferative glomerulonephri-
tis and the patient was given 1g bolus methylprednisolone
intravenously for 3 days and after that prednisone orally
(60mg/day).2 And in the study by Nie et al., as HSP nephri-
tis (severe) was conﬁrmed, intravenous methylprednisolone
(500mg/d) was given to the patient for 3 days followed by oral
dehydrocortisone of 30mg/d.3 The two patients got complete
remission in pancreas and kidney.
HSP is a rare and benign cause of acute pancreatitis. This
complication could occur before the characteristic rash and
shown as an initial manifestation of HSPN. Steroids could
improve the outcome of the HSPN patients with pancreatitis.
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espuesta a acetazolamida en paciente con calcinosis
umoral
esponse to acetazolamide in a patient with tumoral calcinosis
r. Director:
a calcinosis tumoral (CT) es un raro trastorno del
etabolismodel fósforo que se caracteriza por la formaciónde
umores periarticulares de fosfato de calcio1. La enfermedad
s resultado de un defecto en la excreción renal de fósforo,
ebido a mutaciones en el factor de crecimiento de ﬁbroblas-
os 23 (FGF23), Klotho y N-acetilgalactosaminiltransferasa-3
GALNT3). La pérdida de función de FGF23 trae como resul-
ado el aumento de la reabsorción tubular del fósforo, seguido
el depósito en los tejidos subcutáneos2.
Paciente varón de 23 an˜os de edad, sin antecedentes impor-
antes, inició su padecimiento a la edad de 18 an˜os, con la
resencia de una masa en la región dorsal y externa del glúteo
muslo derecho. El paciente informó del aumento progresivo
el taman˜o de la masa relacionado con actividad física, así
omo limitación de la función y dolor de la extremidad afec-
ada. Seis meses antes de su ingreso a nuestra institución, se
e realizó la escisión del tumor con las siguientes medidas:
8×7 cm del muslo derecho y 20×10 cm del glúteo derecho,
on características amorfas.
A su ingreso presentó una masa sólida indolora en la
egión de escisión en la superﬁcie exterior del muslo derecho,
on dimensiones de 10×4×6 cm. Los análisis de laboratorio
eportaron niveles séricos normales de calcio, PA, creatinina,
lbúmina y PTH. La radiografía reveló una masa multinodular
alciﬁcada alrededor de la articulación de la cadera derecha.
La biopsia de la lesión reportó nódulos calciﬁcados amor-
os, algunos rodeados por proliferación de macrófagos y
élulas gigantes tipo osteoclasto, separados por tejido ﬁbroso
enso, consistente con CT (ﬁg. 1). Se realizó un seguimiento de
an˜os, con acetazolamida (agosto de 2008 a octubre de 2011).
a terapia demostró mejoría clínica y cese del crecimiento
e las lesiones en el paciente. No se reportaron desordenes
La ﬁsiopatología de la CT se centra en la anormalidad del
metabolismo del fósforo3. La concentración sérica de fosfato
se regula por la comunicación endocrina entre el esqueleto,
el rin˜ón y el intestino4. Los factores endocrinos implicados en
el metabolismo del fósforo son la 1,25-hidroxivitamina D3, la
hormonaparatiroidea (PTH) y el FGF23. Este último sinergiza la
acción de la PTH, reduciendo la expresión de los cotransporta-
dores NaP(i)-IIa y NaP(i)-IIc en el borde en cepillo del túbulo
proximal renal, aumentando la excreción renal de fósforo5.
El FGF23 es una glicoproteína, formada por 251 aminoá-
cidos con una región N-terminal y una C-terminal hecha de
71 aminoácidos6. Promueve la excreción de fósforo mediante
la reducción de la expresión de los cotransportadores NaP(i)
en el cepillo de la célula tubular proximal3. La unión de FGF23
a su receptor FGFR1c necesita ineludiblemente de Klotho para
formar un heterodímero funcional7. El FGF23 es glucosilada
por GALNT38. Solo la proteína completa de FGF23 tiene activi-
dad biológica. Cualquier alteración en estos puntos daría lugar
a un aumento de la reabsorción tubular de fósforo, que es lo
que ocurre en la CT3.
La enfermedad se maniﬁesta con hiperfosfatemia y
depósito masivo de calcio en tejido subcutáneo, siendo los
principales síntomas que afectaban al paciente3. Esta enfer-
medad es más frecuente en mujeres y en afroamericanos,
con un inicio de presentación en la infancia o la adolescencia
temprana2.
El tratamiento deCT se divide en la extirpación quirúrgica y
el tratamientomédico. La extirpaciónquirúrgica de la lesión es
un tratamiento bien documentado, sin embargo la recurrencia
es común. Además, el paciente demostró recidiva tras su
extirpación quirúrgica, debido probablemente a pobre
circunscripción9. El tratamiento médico es preferible debido
a la naturaleza metabólica de la enfermedad. Las terapias
descritas incluyen la restricción de fosfato de la dieta,cido-base durante su uso. Se realizó radiografía de control 7
n˜os después del inicio del tratamiento, y es muy importante
otar queno se observa incremento del taman˜o de las lesiones
ﬁg. 2).antiácidos, fármacos fosfatúricos y aglutinantes de fosfato.
Sin embargo, la extirpación quirúrgica combinada con la pri-
vación de fosfato y el uso de acetazolamida, ha demostrado
ser la terapia más eﬁcaz10.
